Catch up on what happened in optometry during the week of October 21-October 25.

Dry eye increases susceptibility to psychiatric disorders and chronic pain syndromes, investigators reported at the 2024 American Academy of Ophthalmology meeting.

The data showed a reduction in the GA lesion growth rate of 15.3% versus placebo from 6 to 24 months and a slowing in GA growth rate of 13.4% from baseline to 24 months.

The company previously released positive data results from the pivotal Phase 3 CLARITY study in April, with the NDA submitted in August of this year.

Visual impairment has been consistently identified as a “robust risk factor” in the development of dementia.

The company noted that new OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal degeneration.

The OCS-01 eye drops, which utilize an OPTIREACH formulation of high concentration dexamethasone, are intended to be a non-invasive topical treatment.

From neuro-ophthalmic cases to diabetes, EyeCon sported many hot topics.

The study estimated that found approximately 4.22 million people in the US have glaucoma, with as many as 1.49 million people with vision-affecting glaucoma.

An optometrist describes her journey as the first retina optometrist in Colorado.

Catch up on what happened in optometry during the week of October 14-October 18.

Bascom Palmer is piloting a program to provide triage telehealth appointments for patients experiencing eye care emergencies.

Miriam Korik, OD, and Justin Kwan, OD, FAAO, discuss the shift of myopia management from a specialty to a vital aspect of primary care optometry, emphasizing the need for more practitioners to integrate effective strategies and collaborate for better patient outcomes.

The study is now expected to be fully enrolled with all 300 patients randomized by the end of 2024.

Showcasing your practice’s eyewear collections plays a huge role in your success and helps differentiate you from your competitors.